WHY THEY HATE IVERMECTIN SO MUCH
IVERMECTIN CURES CANCER
Year 2021 Studies (3) Indicating That Ivermectin May Be Possible Cure For Esophageal Squamous Cell Carcinoma, Colorectal Cancer And Breast Cancers
1) Research Open Access Published: 07 December 2021
"Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
BMC Cancer volume 21, Article number: 130
Abstract - Background
Esophageal squamous cell carcinoma (ESCC) is the most predominant primary malignant tumor among worldwide, especially in China. To date, the successful treatment remains a mainly clinical challenge, it is imperative to develop successful therapeutic agents.
Methods
The anti-proliferative effect of ivermectin on ESCC is investigated in cell model and in nude mice model. Cell apoptosis was assessed using flow cytometry, TUNEL assay and western blotting. Mitochondrial dysfunction was determined by reactive oxygen species accumulation, mitochondrial membrane potential and ATP levels.
Results
Our results determined that ivermectin significantly inhibited the proliferation of ESCC cells in vitro and in vivo. Furthermore, we found that ivermectin markedly mediated mitochondrial dysfunction and induced apoptosis of ESCC cells, which indicated the anti-proliferative effect of ivermectin on ESCC cells was implicated in mitochondrial apoptotic pathway. Mechanistically, ivermectin significantly triggered ROS accumulation and inhibited the activation of NF-κB signaling pathway and increased the ratio of Bax/Bcl-2.
Conclusions
These finding indicated that ivermectin has significant anti-tumour potential for ESSC and may be a potential therapeutic candidate against ESCC.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-09021-x
2) Front. Pharmacol., 13 August 2021 | https://doi.org/10.3389/fphar.2021.717529
"Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth"
Infection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng, China
Colorectal cancer (CRC) is the third most common cancer worldwide and still lacks effective therapy. Ivermectin, an anti-parasitic drug, has been shown to possess anti-inflammation, anti-virus, and antitumor properties. However, whether ivermectin affects CRC is still unclear. The objective of this study was to evaluate the influence of ivermectin on CRC using CRC cell lines SW480 and SW1116. We used CCK-8 assay to determine the cell viability, used an optical microscope to measure cell morphology, used Annexin V-FITC/7-AAD kit to determine cell apoptosis, used Caspase 3/7 Activity Apoptosis Assay Kit to evaluate Caspase 3/7 activity, used Western blot to determine apoptosis-associated protein expression, and used flow cytometry and fluorescence microscope to determine the reactive oxygen species (ROS) levels and cell cycle. The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, followed by promoting cell apoptosis and increasing Caspase-3/7 activity. Besides, ivermectin upregulated the expression of proapoptotic proteins Bax and cleaved PARP and downregulated antiapoptotic protein Bcl-2. Mechanism analysis showed that ivermectin promoted both total and mitochondrial ROS production in a dose-dependent manner, which could be eliminated by administering N-acetyl-l-cysteine (NAC) in CRC cells. Following NAC treatment, the inhibition of cell growth induced by ivermectin was reversed. Finally, IVERMECTIN at low doses (2.5 and 5 µM) INDUCED CRC CELL ARREST. Overall, IVERMECTIN SUPPRESSED CELL PROLIFERATION by promoting ROS-mediated mitochondrial apoptosis pathway and inducing S phase arrest in CRC cells, SUGGESTING THAT IVERMECTIN MIGHT BE A NEW POTENTIAL ANTICANCER DRUG THERAPY FOR HUMAN COLORECTAL CANCER AND (((OTHER CANCERS))).
https://www.frontiersin.org/articles/10.3389/fphar.2021.717529/full
3) Use of the Anti-Parasitic Drug Ivermectin to Treat Breast Cancer
Lee, Peter P. MD
Oncology Times: May 5, 2021 - Volume 43 - Issue 9 - p 10
OUR GROUP FOUND THAT IVERMECTIN, AN ANTI-PARASITIC DRUG USED WORLDWIDE SINCE 1975 TO TREAT CLOSE TO 1 BILLION PEOPLE PRIMARILY FOR RIVER BLINDNESS AND OTHER PARASITIC INFECTIONS, PROMOTES ICD IN BREAST CANCER CELLS.
Our findings on this novel therapeutic combination published recently in npj Breast Cancer journal (2021; https://doi.org/10.1038/s41523-021-00229-5). THIS IS THE FIRST TIME A RESEARCH TEAM HAS DEMONSTRATED THAT CHECKPOINT INHIBITORS CAN BE USED TO SUCCESSFULLY TREAT BREAST CANCER - WHEN COMBINED WITH IVERMECTIN, AN INEXPENSIVE, EXISTING SAFE DRUG.
Ivermectin is safe and inexpensive at roughly $30 a dose, making it attainable for everyone including cancer patients in developing countries.
https://journals.lww.com/oncology-times/fulltext/2021/05050/use_of_the_anti_parasitic_drug_ivermectin_to_treat.4.aspx